» Articles » PMID: 35568683

Applying an LDL-C Threshold-based Approach to Identify Individuals with Familial Hypercholesterolemia

Overview
Journal J Clin Lipidol
Publisher Elsevier
Date 2022 May 14
PMID 35568683
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Familial hypercholesterolemia (FH) remains underdiagnosed and undertreated. The optimal electronic health record (EHR) screening strategy for FH is unclear.

Objective: To evaluate an LDL-C threshold-based approach of identifying patients with FH from the EHR to determine the optimal LDL-C range for FH consideration.

Methods: Individuals from UT Southwestern Medical Center with an LDL-C level ≥190mg/dL at any time were enrolled in an FH registry. These 5,786 patients were divided into four categories of LDL-C (190- 219, 220 - 249, 250 - 299, and ≥ 300mg/dL) with 100 individuals randomly selected for manual chart review in each category. Chart review included 1) the presence of secondary causes of dyslipidemia, 2) diagnosis of possible/definite FH by modified Simon Broome criteria, and 3) probable/definite FH by modified Dutch Lipid Clinic Network (DLCN) criteria.

Results: Of the 400 individuals with an LDL-C level ≥190mg/dL (mean age 52 years ± 14), the presence of secondary causes increased across each LDL-C category (p < 0.001) with the greatest prevalence in those ≥ 300mg/dL (52%). The prevalence of possible/probable or definite FH also varied by LDL-C category, with the highest prevalence of FH by Simon Broome criteria in the 220 - 249mg/dL category (52%) and by DLCN criteria in the 250 - 299mg/dL category (46%).

Conclusions: Among those with LDL-C ≥ 190mg/dL, the prevalence of secondary causes increased markedly with higher LDL-C, while the diagnosis of FH has a parabolic relationship. Patients with intermediate LDL-C (220 - 299mg/dL) may be the optimal group to prioritize for FH screening.

Citing Articles

Lipid Control and Medical Costs Among Patients With and Without Established Atherosclerotic Cardiovascular Disease Followed in a Brazilian Private Healthcare System.

de Barros E Silva P, Szneider H, Garcia D, Furlan V, Lopes R Glob Heart. 2024; 19(1):65.

PMID: 39157208 PMC: 11328683. DOI: 10.5334/gh.1345.


Screening and clinical characteristics analysis of familial hypercholesterolemia in a tertiary public hospital.

Shen T, Fu Q, Luo R, Wan Y, Jiang L Front Cardiovasc Med. 2023; 10:1237261.

PMID: 37621559 PMC: 10445126. DOI: 10.3389/fcvm.2023.1237261.


Serum Low Density Lipoprotein Cholesterol Concentration Is Not Dependent on Cholesterol Synthesis and Absorption in Healthy Humans.

Stellaard F, Baumgartner S, Mensink R, Winkens B, Plat J, Lutjohann D Nutrients. 2022; 14(24).

PMID: 36558527 PMC: 9781611. DOI: 10.3390/nu14245370.


A mixed methods study of the awareness and management of familial hypercholesterolaemia in Irish general practice.

Homeniuk R, Gallagher J, Collins C Front Med (Lausanne). 2022; 9:1016198.

PMID: 36314005 PMC: 9596980. DOI: 10.3389/fmed.2022.1016198.


Implementation of a biochemical, clinical, and genetic screening programme for familial hypercholesterolemia in 26 centres in Spain: The ARIAN study.

Arrobas Velilla T, Brea A, Valdivielso P Front Genet. 2022; 13:971651.

PMID: 36105085 PMC: 9465084. DOI: 10.3389/fgene.2022.971651.